

Serial No. 10/081,126

Docket No. 17413 (AP)

### CLAIMS

The following listing of claims will replace all previous versions of claims presented in this application:

1. - 38. (Canceled).

39. (Previously presented) A method of extending corneal graft survival following corneal transplantation in a patient, comprising administering to said patient an effective amount of a pharmaceutical composition comprising an indolinone vascular endothelial growth factor receptor-3 (VEGFR-3) kinase inhibitor, whereby lymphangiogenesis is suppressed in the cornea of said patient.

40. (Currently amended) The method of claim 39, wherein said VEGFR-3 kinase inhibitor ~~binds the~~ binds to the VEGFR-3 catalytic domain.

41. (Currently amended) The method of claim 39, wherein said indolinone is selected from the group consisting of 3(2,4-dihydroxy-benzylidene)-1,3-dihydro-indol-2-one; 3-(3-fluoro-4-methoxy-benzylidene)-1,3-dihydro-indol-2-one; and 3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one.

42. (Previously presented) The method of claim 41, where said indolinone is 3(2,4-dihydroxy-benzylidene)-1,3-dihydro-indol-2-one.

43. (Previously presented) The method of claim 41, where said indolinone is 3-(3-fluoro-4-methoxy-benzylidene)-1,3-dihydro-indol-2-one.

44. (Previously presented) The method of claim 41, where said indolinone is 3-(4-dimethylamino-naphthalen-1-ylmethylene) -1,3-dihydro-indol-2-one.

45. (Previously presented) The method of claim 39, further comprising administering to said patient an anti-angiogenic agent.

46. (Previously presented) The method of claim 39 or claim 45, further comprising administering to said patient an immunosuppressive agent.

47. (Previously presented) The method of claim 39, wherein said pharmaceutical composition is administered prior to corneal transplantation.

48. (Previously presented) The method of claim 39, wherein said pharmaceutical composition is administered subsequent to corneal transplantation.

Serial No. 10/081,126

Docket No. 17413 (AP)

49. (Previously presented) The method of claim 39, comprising administering to said patient an effective amount of a pharmaceutical composition comprising a VEGFR-3 kinase inhibitor two or more times.

50. (Previously presented) The method of claim 49, comprising repeated administration over a period of at least one month.

51. (Previously presented) The method of claim 49, comprising repeated administration over a period of at least six months.

52. (Previously presented) The method of claim 49, comprising:

(a) administering to said patient prior to corneal transplantation a pharmaceutical composition comprising a VEGFR-3 kinase inhibitor; and

(b) administering to said patient subsequent to corneal transplantation a pharmaceutical composition comprising a VEGFR-3 kinase inhibitor,

whereby lymphangiogenesis is suppressed in the cornea of said patient.

53. (Previously presented) The method of claim 39, comprising systemic administration of said pharmaceutical composition.

54. (Previously presented) The method of claim 39, comprising local administration of said pharmaceutical composition.

55. (Previously presented) The method of claim 54, comprising topical administration of said pharmaceutical composition.

56. (Previously presented) The method of claim 54, comprising local injection of said pharmaceutical composition.

57. (Previously presented) The method of claim 54, said pharmaceutical composition released from an intraocular or periocular implant.